Publication
Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ignace Vergote, David Cibula, Matthew Powell, Annouschka Laenen, Els Van Nieuwenhuysen, Samet Topuz, Antonio González-Martín, Keiichi Fujiwara, Sufia Safina, Andrea Bagaméri, Matthew Oliver, Jung-Yun Lee, Vanda Salutari, Jacob Korach, Chien-Hsing Lu, Radosław Mądry, Christof Vulsteke, Nicoletta Colombo, Jalid Sehouli, Jaroslav Klat, Eduardo Yañez Ruiz, Lucy Gilbert, Patricia Pautier, Beatriz Pardo, Frederic Kridelka, Jing Wei, Sarper Toker, Karin Yamada, Robert L Coleman, ENGOT-OV43/GOG-3036/KEYLYNK-001 investigators
- Source
- PubMed
- Retrieved
- Sep 14, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260914-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: The PARP inhibitor olaparib is used for first-line maintenance of patients with BRCA-mutated advanced ovarian cancer. We aimed to evaluate the efficacy and safety of pembrolizumab plus chemotherapy followed by pembrolizumab plus olaparib maintenance with or without bevacizumab as…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT03740165registry_reference1.00
Candidate 1
- cancerMalignant Ovarian Neoplasmdictionary0.60
Registered trialsNCT03740165
Curated evidence
Evidence citing this paper (0)
Data not yet available